

# TRAF2 (C-20): sc-876

## BACKGROUND

Tumor necrosis factor (TNF)-activated cell signaling is mediated primarily through the TNF receptor 1 (TNF-R1) and, to a lesser extent, TNF-R2. Both TNF receptors are members of the expanding TNF receptor superfamily which includes the Fas antigen and CD40. Potential insight into an understanding of TNF receptor-mediated signaling was provided by the identification of two related proteins, TRAF1 and TRAF2 (for TNF receptor-associated factors 1 and 2, respectively). Both function to form heterodimeric complexes and associate with the cytoplasmic domain of TNF-R2. A third member of this protein family, alternatively designated CD40 bp, CRAF1, LAP1 or TRAF3, has been identified and shown to associate with the cytoplasmic domain of CD40. The similarity between a specific region of TRAF3 with regions of TRAF1 and TRAF2 define a "TRAF-C" domain that is necessary and sufficient for CD40 binding and homodimerization.

## CHROMOSOMAL LOCATION

Genetic locus: TRAF2 (human) mapping to 9q34.3; Traf2 (mouse) mapping to 2 A3.

## SOURCE

TRAF2 (C-20) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the C-terminus of TRAF2 of human origin.

## PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-876 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## APPLICATIONS

TRAF2 (C-20) is recommended for detection of TRAF2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

TRAF2 (C-20) is also recommended for detection of TRAF2 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for TRAF2 siRNA (h): sc-29509, TRAF2 siRNA (m): sc-36711, TRAF2 shRNA Plasmid (h): sc-29509-SH, TRAF2 shRNA Plasmid (m): sc-36711-SH, TRAF2 shRNA (h) Lentiviral Particles: sc-29509-V and TRAF2 shRNA (m) Lentiviral Particles: sc-36711-V.

Molecular Weight of TRAF2: 50 kDa.

Positive Controls: TRAF2 (h7): 293T Lysate: sc-178076 or Jurkat whole cell lysate: sc-2204.


## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## DATA



TRAF2 (C-20): sc-876. Western blot analysis of TRAF2 expression in non-transfected 293T: sc-117752 (A), human TRAF2 transfected 293T: sc-178076 (B) and Jurkat (C) whole cell lysates.



TRAF2 (C-20): sc-876. Immunofluorescence staining of methanol-fixed, TRAF2-transfected COS cells showing peripheral cytoplasmic localization.

## SELECT PRODUCT CITATIONS

- Devergne, O., et al. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NFκB activation. *Mol. Cell. Biol.* 16: 7098-7108.
- He, B., et al. 2010. The transmembrane activator TAC1 triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. *Nat. Immunol.* 11: 836-845.
- Ndour, P.A., et al. 2010. Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1. *Cell. Signal.* 22: 303-313.
- Knox, P.G., et al. 2011. The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas. *J. Cell Biol.* 192: 391-399.
- Sun, D., et al. 2011. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). *Nat. Immunol.* 12: 853-860.
- Huang, Y., et al. 2011. UXT-V1 protects cells against TNF-induced apoptosis through modulating complex II formation. *Mol. Biol. Cell* 22: 1389-1397.
- Ndour, P.A., et al. 2012. Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells. *J. Virol.* 86: 3934-3943.
- Pérez-Chacón, G., et al. 2012. TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice. *J. Immunol.* 189: 1053-1061.


 MONOS  
Satisfation  
Guaranteed

Try **TRAF2 (F-2): sc-136999** or **TRAF2 (F-4): sc-137048**, our highly recommended monoclonal alternatives to TRAF2 (C-20). Also, for AC, HRP, FITC, PE, Alexa Fluor® 488 and Alexa Fluor® 647 conjugates, see **TRAF2 (F-2): sc-136999**.